Literature DB >> 3859361

Candida rugosa in immunocompromised infection. Case reports, drug susceptibility, and review of the literature.

A M Sugar, D A Stevens.   

Abstract

Candida rugosa was isolated from two patients. One patient had acute leukemia and developed invasive disease due to this yeast on two occasions while granulocytopenic. Her infection was eventually cured after treatment with amphotericin B. In another immunocompromised patient, the yeast was isolated from the sputum in the presence of a pulmonary infiltrate, but there was no other evidence for a pathogenic role. Antifungal susceptibility testing of the first patient's isolate and three environmental isolates showed all four to be susceptible to amphotericin B, miconazole, and flucytosine, and only the patient isolate was resistant to ketoconazole. These results suggest possibilities for therapy in future encounters. It appears that C. rugosa, a common pathogen in cattle, can be pathogenic in humans under the appropriate circumstances.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3859361     DOI: 10.1002/1097-0142(19850715)56:2<318::aid-cncr2820560219>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

Review 1.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 2.  Fungal infections of the immunocompromised host: clinical and laboratory aspects.

Authors:  C E Musial; F R Cockerill; G D Roberts
Journal:  Clin Microbiol Rev       Date:  1988-10       Impact factor: 26.132

3.  Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.

Authors:  M A Pfaller; D J Diekema; A L Colombo; C Kibbler; K P Ng; D L Gibbs; V A Newell
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

4.  DNA fingerprinting of Candida rugosa via repetitive sequence-based PCR.

Authors:  R J Redkar; M P Dubé; F K McCleskey; M G Rinaldi; V G Del Vecchio
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

5.  Candida rugosa: a possible emerging cause of candidaemia in trauma patients.

Authors:  B Behera; R I Singh; I Xess; P Mathur; F Hasan; M C Misra
Journal:  Infection       Date:  2010-07-24       Impact factor: 3.553

6.  In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.

Authors:  D J Diekema; S A Messer; L B Boyken; R J Hollis; J Kroeger; S Tendolkar; M A Pfaller
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

7.  Catheter-associated Candida utilis fungemia in a patient with acquired immunodeficiency syndrome: species verification with a molecular probe.

Authors:  A Alsina; M Mason; R A Uphoff; W S Riggsby; J M Becker; D Murphy
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

8.  Histoplasmosis in hairy cell leukemia: case report and review of the literature.

Authors:  E Weeks; C M Jones; V Guinee; R Shallenberger; G A Sarosi; P A Bunnell
Journal:  Ann Hematol       Date:  1992-09       Impact factor: 3.673

9.  In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis; R N Jones
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

10.  Evaluation of pulsed-field gel electrophoresis as a typing system for Candida rugosa: comparison of karyotype and restriction fragment length polymorphisms.

Authors:  J C Dib; M Dube; C Kelly; M G Rinaldi; J E Patterson
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.